Table 4.
Clinical trials of CAR T cell cocktail or sequential therapy.
| Disease | Authors | Intervention | Targets | N | ORR | CR | Survival | Toxicity | |
|---|---|---|---|---|---|---|---|---|---|
| B-NHL | Wei et al. (62) | Cocktail | CD19+CD22 | 66 | TP53: 88% Non: 87% |
TP53: 50% Non: 45% |
NR | CRS: 91%; ICANS: 9% | |
| Wang et al. (48) | Cocktail | CD19+CD22 | 38 | 72% | 50% | OS, 55% (1y); PFS, 50% (1y) | CRS: 96%; ICANS: 14% | ||
| Cao et al. (64) | Cocktail | CD19+CD22 | 42 | 91% | 81% | OS, 83% (2y); PFS, 83% (2y) | CRS: 96%; ICANS: 21% | ||
| Zeng et al. (183) | Cocktail | CD22+CD19 | 14 | 71% | 50% | OS, 71% (6m); PFS, 50% (6m) | CRS: 93%; GI AE: 29% a | ||
| BL | Liu et al. (184) | Sequential | CD19-CD22-CD20 | 23 | 95% | 86% | PFS, 78% (18m) | CRS: 70%; ICANS: 22% | |
| DHL | Wei et al. (185) | Cocktail | CD19+CD22 | 12 | 83% | 25% | OS, 75% (1y); PFS, 64% (1y) | CRS: 75%; ICANS: 33% | |
| B-ALL | Wang et al. (48) | Cocktail | CD19+CD22 | 51 | 96% | 96% c | OS, 63% (1y); PFS, 53% (1y) | CRS: 96%; ICANS: 14% | |
| Yan et al. (186) | Cocktail | CD19+CD22 | 22 | 100% | 100% | OS, 67% (1y); PFS, 59% (1y) | CRS: 87%; GVHD: 30% b | ||
| Liu et al. (187) | Sequential | CD19-CD22 | 21 | 95% | 95% | OS, 89% (1y); EFS, 68% (18m) | CRS: 52% | ||
| Pan et al. (188) | Sequential | CD19-CD22 | 20 | 100% | 100% | OS, 92% (1y); LFS, 80% (1y) | CRS: 90%; ICANS: 20% | ||
| MM | Yan et al. (189) | Cocktail | CD19+BCMA | 21 | 95% | 57% | NR | CRS: 90%; ICANS: 10% | |
| Wang et al. (190) | Cocktail | CD19+BCMA | 62 | 92% | 60% | Median PFS: 18.3m | CRS: 95%; ICANS: 11% | ||
| Shi et al. (71) | Cocktail | CD19+BCMA | 9 | 100% | 100% | NR | CRS: 100% | ||
| Shi et al. (148) | Cocktail | CD19+BCMA | 10 | 100% | 100% | NR | CRS: 100% | ||
| Yan et al. (191) | Cocktail | CD19+BCMA | 10 | 90% | 57% d | NR | CRS: 100% | ||
NHL, non-Hodgkin lymphoma; BL, Burkitt lymphoma; DHL, double-hit lymphoma; ALL, acute lymphoblastic leukemia; MM, multiple myeloma; ORR, overall response rate; CR, complete response; OS, overall survival; PFS, progression-free survival; EFS, event-free survival; LFS, leukemia-free survival; CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; NR, not reported; GI AE, gastrointestinal adverse events.
a
Patients enrolled in the trial had lymphoma involving the gastrointestinal tract.
b
Patients with allo-HSCT history in this trial received allogenic CAR T cells.
c
MRD-negative CR/CRi.
d
stringent CR.